Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.860
-0.030 (-0.77%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data
July 22, 2022
VistaGen Therapeutics (VTGN) stock is falling hard on Friday after the company reported poor results from a Phase 3 study.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2022
July 22, 2022
Upgrades
Via
Benzinga
VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study
July 22, 2022
Via
Benzinga
Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
April 16, 2022
Deals, financings, trials and approvals in biotech in China this week.
Via
Talk Markets
Recap: VistaGen Therapeutics Q3 Earnings
February 10, 2022
VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 10, 2022
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset
July 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 19, 2022
Tuesday saw 37 companies set new 52-week lows.
Via
Benzinga
Looking Into VistaGen Therapeutics's Return On Capital Employed
June 28, 2022
Benzinga Pro data, VistaGen Therapeutics (NASDAQ:VTGN) reported Q4 sales of $38.90 thousand. Earnings fell to a loss of $16.69 million, resulting in a 58.41% decrease from last quarter.
Via
Benzinga
Earnings Scheduled For June 23, 2022
June 23, 2022
Companies Reporting Before The Bell • Jerash Holdings (US) (NASDAQ:JRSH) is projected to report quarterly earnings at $0.07 per share on revenue of $30.14 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 15, 2022
On Friday, 137 stocks made new 52-week lows.
Via
Benzinga
Earnings Preview For VistaGen Therapeutics
June 22, 2022
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-06-23. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 05, 2022
During Tuesday's session, 539 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 15, 2022
Wednesday's session saw 269 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
June 13, 2022
During Monday's trading, 1214 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
June 10, 2022
On Friday, 422 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
May 23, 2022
On Monday, 149 companies reached new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
May 24, 2022
On Tuesday, 540 companies set new 52-week lows.
Via
Benzinga
7 Cheap Biotech Stocks to Buy Now
May 19, 2022
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 14, 2022
On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 07, 2022
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 17, 2022
Gainers Creative Medical Tech (NASDAQ:CELZ
Via
Benzinga
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
February 14, 2022
According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
February 22, 2022
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to...
Via
Benzinga
VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
October 14, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 26, 2021
Gainers MorphoSys (NASDAQ:MOR) stock move...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
August 13, 2021
Gainers Cellect Biotechnology (NASDAQ:APOP
Via
Benzinga
Recap: VistaGen Therapeutics Q1 Earnings
August 12, 2021
Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the...
Via
Benzinga
Looking Into VistaGen Therapeutics's Return On Capital Employed
July 13, 2021
In Q4, VistaGen Therapeutics (NASDAQ:VTGN) posted sales of $441.90 thousand. Earnings were up 17.36%, but VistaGen Therapeutics still reported an overall loss of $6.22 million....
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.